VivoSeq
Other

Metastatic NSCLC

0

Pipeline Programs↗

15

Active Trials↗

10

Companies Involved↗

Metastatic NSCLC is an early-stage landscape with 0 programs across 10 companies. The most active players are Novartis, ImmuneSensor Therapeutics Inc., Changchun GeneScience Pharmaceutical Co., Ltd..

Intelligence

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

22/100

Mech. Concentration

N/A

Completion Rate

71/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalI

ImmuneSensor Therapeutics Inc.

0 programs

PreclinicalChangchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.

0 programs

PreclinicalH

Hellenic Oncology Research Group

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalM

Maia Biotechnology

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

40

clinical trials

Completed12 · 30%
Unknown status7 · 18%
Recruiting6 · 15%
Active, not recruiting6 · 15%
Terminated5 · 13%
Not yet recruiting3 · 8%
Other1 · 3%

Clinical Trials

Trial Activity

40 trials

Prospective Trial of Induction Immunotherapy in Locally Advanced or Oligometastatic NSCLC Without a Primary Curative Option
Recruiting·KKlinikum Esslingen·N/A·NCT04926584·50 enrolled
Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)
Recruiting·GGazi University·N/A·NCT07394062·400 enrolled
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Recruiting·MMaia Biotechnology·Phase 3·NCT06908304·300 enrolled
ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
Recruiting·FFudan University·Phase 2·NCT06775743·53 enrolled
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
Recruiting·CCatalYm GmbH·Phase 2·NCT07246863·131 enrolled
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors
Recruiting·OOncoC4, Inc.·Phase 3·NCT05671510·630 enrolled
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)
Active, not recruiting·Eli Lilly logoEli Lilly·Phase 3·NCT02411448·545 enrolled
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)
Active, not recruiting·PPeking Union Medical College Hospital·Phase 2·NCT05599789·47 enrolled
Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC
Active, not recruiting·FFox Chase Cancer Center·Phase 2·NCT03527108·36 enrolled
Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC
Active, not recruiting·EETOP IBCSG Partners Foundation·Phase 2·NCT03965468·96 enrolled
A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Naïve Patients With Metastatic NSCLC
Active, not recruiting·—·Phase 2·NCT05144529·38 enrolled
Dupilumab_Metastatic NSCLC
Active, not recruiting·—·Phase 1/2·NCT05013450·33 enrolled
SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC
Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07489703·30 enrolled
A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)
Not yet recruiting·JJun Zhang, MD, PhD·Phase 2·NCT05859217·40 enrolled
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%
Not yet recruiting·SSwiss Cancer Institute·Phase 2·NCT07020065·156 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)